Developer of Revolutionary "Powder" Epinephrine Auto-Injector Raises $12 Million


As we reported back in 2016, Windgap Medical – a small company headquartered in Watertown, MA – is developing a revolutionary new epinephrine auto-injector that promises a radical departure from auto-injectors on the market today.

In a recent Securities and Exchange Commision (SEC) filing, the company disclosed that they have raised $12 million from 106 investors as part of a $27 million round.

Windgap Patent
Windgap Device Patent Filing
Click to visit sponsor

That round will help fund continued development of an auto-injector whose design has already garnered multiple patents. CEO Christopher Stepanian describes the patents as follows:

The focus of all of our published patents is on the idea of facilitating wet/dry mixing in the drug delivery space. Our goal is to enable the reconstitution or mixing of drugs in a controlled way in a very small volume. Our approaches are focused on situations where the stability of a drug might be an issue and ease-of-use is a concern.

In essence, the Windgap design separates wet and dry components and mixes them at the time of use. The separation allows for a smaller form factor while providing for much longer shelf-life and increased temperature stability, thus alleviating the need to keep the device in relatively cool places.

Click to visit sponsor

For more information on Windgap and their auto-injector, click here see our interview with Christopher Stepanian.

Delivering the Next Generation Auto-Injector

Source: Windgap Medical Form D – Securities and Exchange Commission
Print or share this article
Print or share this article
Click to visit sponsor
Dave Bloom
Dave Bloom
Dave Bloom is CEO and "Blogger in Chief" of

Find Allergy-Friendly Products


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.